Cencora, Inc. (NYSE:COR) Shares Sold by Farmers Trust Co.

Farmers Trust Co. cut its stake in shares of Cencora, Inc. (NYSE:COR) by 1.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,234 shares of the company’s stock after selling 158 shares during the quarter. Farmers Trust Co.’s holdings in Cencora were worth $1,850,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Range Financial Group LLC increased its holdings in Cencora by 272.8% in the fourth quarter. Range Financial Group LLC now owns 9,114 shares of the company’s stock valued at $2,048,000 after buying an additional 6,669 shares in the last quarter. Diversified Trust Co increased its stake in Cencora by 0.9% in the 4th quarter. Diversified Trust Co now owns 49,020 shares of the company’s stock valued at $11,014,000 after purchasing an additional 461 shares in the last quarter. Fortem Financial Group LLC raised its holdings in Cencora by 2.1% during the fourth quarter. Fortem Financial Group LLC now owns 5,201 shares of the company’s stock worth $1,169,000 after purchasing an additional 109 shares during the last quarter. Insight Wealth Strategies LLC boosted its position in Cencora by 124.6% during the fourth quarter. Insight Wealth Strategies LLC now owns 20,249 shares of the company’s stock worth $4,549,000 after purchasing an additional 11,232 shares in the last quarter. Finally, Iowa State Bank grew its holdings in Cencora by 3.2% in the fourth quarter. Iowa State Bank now owns 6,375 shares of the company’s stock valued at $1,432,000 after purchasing an additional 198 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Wells Fargo & Company decreased their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday, December 13th. Barclays increased their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Leerink Partners cut their price objective on Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. UBS Group increased their target price on Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Finally, StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.60.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total value of $5,071,822.20. Following the completion of the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at approximately $4,649,648.88. This trade represents a 7.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 94,696 shares of company stock valued at $22,862,734. Insiders own 15.80% of the company’s stock.

Cencora Trading Up 1.6 %

NYSE:COR traded up $3.64 during mid-day trading on Wednesday, reaching $237.88. The company’s stock had a trading volume of 1,030,304 shares, compared to its average volume of 1,230,890. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The stock has a market cap of $45.98 billion, a P/E ratio of 31.68, a P/E/G ratio of 1.54 and a beta of 0.49. The company’s fifty day simple moving average is $237.38 and its two-hundred day simple moving average is $233.51. Cencora, Inc. has a twelve month low of $209.32 and a twelve month high of $253.27.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.92%. This is an increase from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. Cencora’s payout ratio is presently 29.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.